Recent briefings through mid-August 2026 contained no Eli Lilly-specific corporate disclosures. The dominant macro themes across the period included the Strait of Hormuz standoff, with President Trump hardening his stance on Iran and vessel attacks driving volatility across energy, equity, and foreign exchange markets [Brief - 2026-08-11]. Broader equity markets experienced sharp swings during the week ending 7 August, while the Nasdaq 100 added $3.5 trillion in market capitalisation over four trading days through 6 August, driven by technology earnings and AI-related spending activity [Brief - 2026-08-07] [Brief - 2026-08-05].
Eli Lilly's trailing twelve-month revenue stood at $79.67 billion as of 30 June 2026, representing year-over-year growth of 47.67%. Net income for the same period was $26.71 billion, yielding a net margin of 33.53%. EPS grew 26.23% year-over-year. The company reported cash of $8.95 billion against total debt of $54.91 billion. The price-to-earnings ratio was recorded at 40.77 [SEC 10-Q - LLY - 2026-06-30].
Insider activity in August 2026 recorded eight transactions with a net selling direction, totalling a net disposed value of approximately $8.32 million [SEC Form 4 - LLY - 2026-08]. No notable 13F institutional holding changes were available in the provided data for this reporting period.
The US Treasury yield curve as of the report date reflected a normal shape, with the 10-year yield at 4.72% and the 2-year yield at 4.25% [FRED DGS10] [FRED DGS2]. This report was triggered by a new SEC filing associated with Eli Lilly during the current reporting cycle.